Loading organizations...
Biomark Capital is a venture capital and private equity firm that finances and supports companies in healthcare and life sciences. The firm identifies and nurtures businesses with novel approaches, offering capital and operational guidance through various development stages. Its strategy relies on understanding scientific advancements and market needs.
Founded in 2013, Biomark Capital’s Managing Director, David Wetherell, leveraged his experience as a high-tech CEO and two decades in venture capital. The firm emerged from the insight that specialized investment and hands-on support were crucial for transformative companies in the complex healthcare and life science industries.
Biomark Capital partners with innovative healthcare and life science entities, providing capital and strategic direction. Its vision is to accelerate the development and market entry of scientific and medical technologies. They aim to empower portfolio companies, enabling significant impact and success, ultimately advancing global health.
Biomark Capital has 1 tracked investment across 1 company. The latest tracked deal is $35.0M Series B in Eden Biologics in June 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 20, 2014 | Eden Biologics | $35.0M Series B | Milestone Capital | Allen Chao, CDIB Capital Group, Fubon Ventures, Hotung Venture Group, Kleiner Perkins, President International Development Corporation, Taian Venture Capital, Taishin Financial Holdings |
